Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

On Sunday, Arcellx, Inc. (NASDAQ:ACLX) revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).

The data will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition. Anito-cel is partnered with Kite, a Gilead Science Inc’s (NASDAQ:GILD) company.

Also Read: Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Myeloma Cell Therapies: Morgan Stanley

The Phase 2 iMMagine-1 data are from an October 31 data cutoff date, with a median follow-up of 9.5 months ...

Full story available on Benzinga.com